Beloved TV host Ananda Lewis shares her story and a message to Black women about prioritizing their health in the new year.

The FDA has approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) to treat unresectable or metastatic hormone receptor HR+, HER2- breast cancer in adult patients who have previously received endocrine-based therapy and chemotherapy for unresectable or metastatic disease, according to a news release.

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. The treatment, jointly developed with the Japanese company,

It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1

The increase in breast cancer rates among younger patients is occurring as the incidence of other early-onset cancers — including colorectal, gastric, kidney and liver cancer — is also on the rise, though cancer among patients under 50 is still relatively rare overall, Dr. Partridge said.

Danielle Fishel is sharing an update about her health, saying she has completed “active cancer treatment” following her announcement in August that she was diagnosed with DCIS, which stands for ductal carcinoma in situ and is a form of breast cancer.

Breast cancer is the second leading cause of cancer death in women. Early detection results in 99% five-year survival rates.

If you have breast cancer, you will have changes in your breast. These may be lumps or changes in the size or color of your breast, or changes in the appearance of your nipples. Breast cancer ...

The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.

"Boy Meets World" star Danielle Fishel said she is finished with radiation treatment for cancer and opened up about the side effects.

Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39, on Monday after rising as much as 9.7% earlier. Over the past three years, the stock posted a daily gain of more than 8% only four times.

As cancer treatment costs have increased, identifying and treating early-stage cancer sooner reduces expenses and improves patient outcomes.